CN101410130A - 新颖的免疫调节肽 - Google Patents

新颖的免疫调节肽 Download PDF

Info

Publication number
CN101410130A
CN101410130A CNA2004800190000A CN200480019000A CN101410130A CN 101410130 A CN101410130 A CN 101410130A CN A2004800190000 A CNA2004800190000 A CN A2004800190000A CN 200480019000 A CN200480019000 A CN 200480019000A CN 101410130 A CN101410130 A CN 101410130A
Authority
CN
China
Prior art keywords
nogo
epitope
antigen
peptide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800190000A
Other languages
English (en)
Chinese (zh)
Inventor
L·斯坦曼
H·加伦
P·冯杜拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayhill Therapeutics Inc
Leland Stanford Junior University
Original Assignee
Bayhill Therapeutics Inc
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayhill Therapeutics Inc, Leland Stanford Junior University filed Critical Bayhill Therapeutics Inc
Publication of CN101410130A publication Critical patent/CN101410130A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
CNA2004800190000A 2003-05-15 2004-05-14 新颖的免疫调节肽 Pending CN101410130A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47059303P 2003-05-15 2003-05-15
US60/470,593 2003-05-15

Publications (1)

Publication Number Publication Date
CN101410130A true CN101410130A (zh) 2009-04-15

Family

ID=33551419

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800190000A Pending CN101410130A (zh) 2003-05-15 2004-05-14 新颖的免疫调节肽

Country Status (7)

Country Link
US (1) US7867976B2 (cg-RX-API-DMAC10.html)
EP (1) EP1633315A4 (cg-RX-API-DMAC10.html)
JP (1) JP2007537985A (cg-RX-API-DMAC10.html)
CN (1) CN101410130A (cg-RX-API-DMAC10.html)
AU (1) AU2004247018A1 (cg-RX-API-DMAC10.html)
CA (1) CA2525966A1 (cg-RX-API-DMAC10.html)
WO (1) WO2004110353A2 (cg-RX-API-DMAC10.html)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055609A1 (en) * 1997-06-06 1998-12-10 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US6531130B1 (en) * 1999-07-06 2003-03-11 The Board Of Trustees Of The Leland Stanford University Treatment of demyelinating autoimmune disease with ordered peptides
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
HUP0203863A3 (en) * 2000-01-12 2008-03-28 Univ Yale Nogo receptor-mediated blockade of axonal growth

Also Published As

Publication number Publication date
US7867976B2 (en) 2011-01-11
WO2004110353A2 (en) 2004-12-23
WO2004110353A3 (en) 2009-04-02
AU2004247018A1 (en) 2004-12-23
CA2525966A1 (en) 2004-12-23
EP1633315A4 (en) 2010-09-08
EP1633315A2 (en) 2006-03-15
US20070280954A1 (en) 2007-12-06
JP2007537985A (ja) 2007-12-27

Similar Documents

Publication Publication Date Title
Monneaux et al. T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MRL/lpr mice
US20110245107A1 (en) Selective differentiation, identification, amd modulation of human th17 cells
US20100203053A1 (en) Method and composition for treating immune complex associated disorders
Shoenfeld et al. Infection and autoimmunity
CN113966224A (zh) 采用补体抑制剂的炎性疾病治疗
AU2002324937A1 (en) Method and composition for treating immune complex associated disorders
Wenhart et al. A fructosylated peptide derived from a collagen II T cell epitope for long-term treatment of arthritis (FIA-CIA) in mice
Skeie et al. Autoimmunity against the ryanodine receptor in myasthenia gravis
Ford et al. An MHC anchor‐substituted analog of myelin oligodendrocyte glycoprotein 35–55 induces IFN‐γ and autoantibodies in the absence of experimental autoimmune encephalomyelitis and optic neuritis
US7867976B2 (en) Nogo epitopic fragments for modulating immune response
Holmes et al. Multiple sclerosis: MHC associations and therapeutic implications
Lee et al. Molecular mimicry in neurological disease: what is the evidence?
Liem et al. Vries-Bouwstra
US11435345B2 (en) Detection and treatment of demyelinating diseases
JP2004512371A (ja) Ｔｉｒｃ７リガンド結合の阻害剤を得るための方法およびその使用
Nandedkar Autoantigens and Insulin Receptor in Type 1 Diabetes
WO2012116210A2 (en) Peptide for the induction of immune tolerance as treatment for systemic lupus erythematosus
US20170159016A9 (en) Selective differentiation, identification, and modulation of human th17 cells
Ford Keep s' myelin: Regulation of autoreactive T cell responses in EAE
Edwards T cell recognition of weak ligands activates negative regulatory pathways
ZA200401576B (en) Method and composition for treating immune complex associated disorders.
Lee et al. Cellular and molecular| ife Sciences: CMLS
Vincent et al. 33 Antibodies and CNS disorders
HK1175839A (en) Methods for improving the design, bioavailability, and efficacy of random sequence polymer compositions via serum protein-based detection of random sequence polymer compositions
Prakken et al. Autoimmunity or immune deficiency? On the role and function of regulatory T cells in chronic arthritis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090415